EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class Treatment for Irritable Bowel Syndrome (IBS)
EnteroBiotix Announces Positive Topline Phase 2a Results with EBX-102-02, a Potential First-in-Class…
NordVPN undergoes independent security assessment, reinforcing security and privacy commitment
LONDON, March 07, 2025 (GLOBE NEWSWIRE) -- NordVPN, a cybersecurity company, has…
Carahsoft Recognized as Institute of Excellence in Sales Premier Sales Employer for 2024
RESTON, Va., March 05, 2025 (GLOBE NEWSWIRE) -- Carahsoft Technology Corp., The…
KFSHRCs Dr. Jackie Ying Named in Forbes 50 Over 50 Global 2025 List
RIYADH, Saudi Arabia, March 04, 2025 (GLOBE NEWSWIRE) -- Dr. Jackie Ying,…
Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2024 Financial Results
Accelerated execution of Phase 2 APEX clinical trial for APG777, with Part…
Apogee Therapeutics Announces Positive Interim Phase 1 Results from the APG990 Healthy Volunteer Trial, Unlocking Potential Maintenance Dosing Every Three and Six Months for APG279 (APG777 + APG990)
Interim Phase 1 results for APG990, a novel half-life extended OX40L antibody,…
New Data Demonstrated Best-in-Class Potential for Casdatifan, a HIF-2a Inhibitor, in Patients with Metastatic Kidney Cancer
A 9.7-month median progression-free survival (mPFS) was reached for the 50mg twice-daily…
Volta Medical Artificial Intelligence-guided Cardiac Ablation Procedure Improves Treatment of Atrial Fibrillation
February 14, 2025 05:30 ET | Source: Volta Medical AI-Guided Cardiac Ablation…
NKGen Biotech Announces Publication of Phase 1 Troculeucel Clinical Trial Results for the Treatment of Alzheimers Disease
February 13, 2025 08:00 ET | Source: NKGen Biotech The results from…
HTX DAO Celebrates First Anniversary with Explosive Growth and Bold Plans for 2025
SINGAPORE, Feb. 12, 2025 /PRNewswire/ -- HTX DAO, a leading decentralized autonomous…
